Leveraging Old Hepatitis C Therapies | NEJM
Older drugs could potentially advance U.S. hepatitis C elimination efforts. The government could act like a business and use all current and historical market information to its advantage.
Related Articles
ABCA3-related interstitial lung disease in a young woman
A 25-year-old non-smoking caucasian woman, with no family history of interstitial lung disease (ILD) or consanguinity, presented with a 6-month history of progressive exertional dyspnoea,…
Abstract/Clinical case submission | ERS Congress 2024
Check the latest information on abstract/clinical case submission for the ERS Congress 2024.
Virtual school on rare lung diseases 2025 – ERS – European Respiratory Society
This ERS/ERN-LUNG collaborative course will present the latest understanding and advice on the management of rare lung diseases.
When Diversity Goals Meet Multiregional Trials | NEJM
To achieve goals focused on diversity in clinical research, trials may need to enroll large numbers of U.S. participants. But diversity initiatives and multiregional strategies…
Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events
Rationale: Inhaled corticosteroids (ICSs) are the cornerstone of asthma treatment and significantly improve morbidity and mortality. Adverse effects of oral corticosteroids are well documented, but…
Canadian wildfire pollution negatively impacted Eastern US residents’ lungs, heart
Despite living far away from Canada, Maryland residents experienced more cardiopulmonary disease health concerns in June 2023 believed to be due to Canadian wildfire pollution,…
Patients with severe eosinophilic asthma, prior biologic use benefit from benralizumab
Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to…
Predatory Journals — What Can We Do to Protect Their Prey? | NEJM
An editorial from the International Committee of Medical Journal Editors recommends actions that authors, institutions, funders, journal editors, and publishers can take to protect against…
The Semi-Sad State of Consumer Protection In Health Care | KFF
In this column, KFF President and CEO Drew Altman explores the state of consumer protections in health care and explains why, even with consumer frustration…
